Request a sponsored account
If your institution has a site license, you may be eligible for a sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Latest Stories
NCI
A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.
NCI
The National Cancer Advisory Board has established an ad hoc working group that will assess cancer centers as part of the designation process. The decision was approved unanimously with one abstention at the NCAB meeting March 17.
NCI
NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.
Sponsored
Colorectal cancer is no longer a disease confined to older adults.
Cancer Policy
Judge Brian E. Murphy, of the U.S. District Court for the District of Massachusetts, temporarily blocked a series of recent changes to the CDC vaccine schedule.
Cancer Policy
The Environmental Protection Agency has proposed a series of amendments to weaken regulations on emissions of ethylene oxide, a gas that is primarily used to sterilize medical devices and equipment.
Cancer Policy
FDA has created a new adverse event reporting system that will consolidate several systems it has for reporting different types of adverse events.
Cancer Policy
The H–1Bs for Physicians and the Healthcare Workforce Act—introduced by Rep. Sanford D. Bishop, Jr. (D-GA) and Rep. Mike Lawler (R-NY)—would exempt physicians and health care workers from a recently imposed $100,000 fee now required to obtain an H-1B visa, which allows foreign nationals in “specialty occupations” to live and work in the U.S. The fee was previously $5,000 to $10,000.
In Brief
Robert A. Winn was named director of Fox Chase Cancer Center. His appointment at Fox Chase will become effective later this summer.
In Brief
The members of the American Association for Cancer Research have elected Robert H. Vonderheide as the AACR President-Elect for 2026-2027.
In Brief
The members of AACR have elected five individuals to serve on the AACR Board of Directors for the 2026-2029 term:
In Brief
Fred Hutch has appointed Mazyar Shadman and Vyshak Alva Venur as deputy chief medical officers, effective April 1.
In Brief
The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.
In Brief
Washington Research Foundation has awarded a $7 million grant to the University of Washington Institute for Protein Design to accelerate the development of new catalytic enzymes and protein-based technologies with applications across medicine, technology, and sustainability.
In Brief
The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Funding Opportunities
Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.
Clinical Roundup
Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.
Clinical Roundup
Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.
Clinical Roundup
Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.
Clinical Roundup
A computational tool infers changes occurring at the ends of the chromosomes housing our DNA, which it does so by detecting structural alterations in cells and tissues captured in images taken of routine medical biopsies, according to a study by scientists at Sanford Burnham Prebys Medical Discovery Institute.
Clinical Roundup
In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells. To fully realize the potential to study biology at this scale, researchers must be equipped to analyze the titanic troves of data generated by these new methods.
Clinical Roundup
Researchers at Inocras, a bioinformatics-led precision health company, and the Broad Institute jointly announced the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers.
Drugs & Targets
NeoGenomics announced the PanTracer LBx test has received coverage from CMS’ Molecular Diagnostics Services Program under Local Coverage Determination - MolDX: Plasma-Based Genomic Profiling in Solid Tumors.
Drugs & Targets
Sartorius is launching an integrated system for the production and quality control of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR T therapies.
Drugs & Targets
The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.
Podcast
FDA’s Center for Biologics Evaluation and Research Director Vinay Prasad is set to leave the agency for a second time amid controversy.
Conversation with The Cancer Letter
Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers.
Regulatory News
Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.
Regulatory News
On Jan. 9, Pierre Fabre Pharmaceuticals received a “complete response letter” from FDA: its application for the T-cell therapy tabelecleucel (Ebvallo) was getting a hard No.
Guest Editorial
The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.
Free
Poisoning one’s political rivals has a long history. In 399 B.C., an Athenian court found Socrates guilty of “impiety and the corruption of youth” and ordered him to drink a fatal dose of hemlock.
Cancer Policy
Yet another U.S. Preventative Services Task Force meeting is postponed—the third missed meeting since the start of the second Trump administration.
Cancer Policy
FDA has approved leucovorin calcium tablets (Wellcovorin), expanding its use for the treatment of cerebral folate deficiency in adult and pediatric patients.
In Brief
The Pezcoller Foundation American Association for Cancer Research International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy and John T. Schiller, both fellows of the AACR Academy, during the AACR Annual Meeting 2026.
In Brief
Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.
In Brief
Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
In Brief
Mass General Brigham has received a $50 million gift for gene and cell therapy research. The gift, made by anonymous donors, will advance clinical research by experts at Mass General Brigham Cancer Institute and throughout the system, to deliver treatments for patients with cancer and other diseases.
In Brief
GRAIL has announced that Bob Ragusa will retire as CEO, effective June 1.
In Brief
The multinational Hepatitis B and HIV Cure Consortium, colloquially known as the BICC, was recently established through the awarding of a five-year, $24 million grant from NIH’s National Institute of Allergy and Infectious Diseases.
In Brief
The University of Illinois Cancer Center has awarded two 2026 Pilot Project Program Awards to pairs of Cancer Center members: Bin He and VK Gadi; and Ece Mutlu and Constance Jeffery.
In Brief
The Advanced Research Projects Agency for Health, an agency within HHS, announced the launch of its Delphi program, an initiative to advance low-cost biosensors that can monitor hormones, inflammatory markers, and other important biochemical signals.
Clinical Roundup
Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma, has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell patients to expect it to come back. The results from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma could upend that prediction.
Clinical Roundup
The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.
Clinical Roundup
Oral mezigdomide in combination with carfilzomib and dexamethasone demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to positive interim phase III results from the SUCCESSOR-2 study.
Clinical Roundup
A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA replication in cancer cells.
Clinical Roundup
Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can “educate” the immune system to find and destroy disease-causing cells throughout the body.
Clinical Roundup
Medically supervised, individualized nutrition therapy—long proven effective in reversing metabolic diseases like type 2 diabetes and obesity—shows promise in extending survival in patients with metastatic pancreatic cancer when used alongside chemotherapy, according to data from a randomized, controlled phase II clinical trial.
Clinical Roundup
New research from a University of Cincinnati Cancer Center study found external beam radiation therapy is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.
Clinical Roundup
Citius Oncology announced positive topline safety and efficacy results from an investigator‑initiated phase I trial evaluating Lymphir (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma.
Clinical Roundup
Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
Clinical Roundup
Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein-Barr virus, a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.
Clinical Roundup
A growing number of U.S. adults consider electronic cigarettes (e-cigarettes) more harmful than conventional cigarettes, UT Southwestern Medical Center researchers show in a study.
Drugs & Targets
FDA has approved Tecvayli (teclistamab-cqyv) plus Darzalez Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Drugs & Targets
Ipsen announced that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab vs R2 in follicular lymphoma).
Podcast
One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
News Analysis
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Conversation with The Cancer Letter
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Conversation with The Cancer Letter
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
Obituary
Erin Geddis Cummings , advocate and founder of Hodgkin’s International, died on Feb. 24, at Martha’s Vineyard Hospital, surrounded by her family. She was 68.
Sponsored
Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows.
Cancer Policy
Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a Swedish physician and philanthropist who founded the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.
Cancer Policy
Rep. Josh Gottheimer (D-NJ) introduced the FIRE Cancer Act on Feb. 27. The piece of legislation seeks to increase grant dollars available to local fire departments, specifically earmarked for cancer prevention, “including providing multi-cancer early detection testing or other forms of preventative tests.”
In Brief
W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus.
In Brief
Bob Gray has retired from his role as Group Statistician, Therapeutics, for the ECOG-ACRIN Cancer Research Group, as of Feb. 28.
In Brief
Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon were appointed members of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center.
In Brief
Fred Hutch Cancer Center announced the recipients of the Harold M. Weintraub Graduate Student Award, which honors the exceptional achievements of graduate students in the biological sciences.
In Brief
M. Saiful Huq, director of medical physics in the Department of Radiation Oncology at the University of Pittsburgh and UPMC Hillman Cancer Center, has been awarded the Inaugural Gold Medal of the Asia and Middle East Society of Therapeutic Radiation and Oncology.
In Brief
Cancer Grand Challenges awards five global teams of scientists up to $25 million each to take on questions that could open entirely new routes for cancer prevention, detection, and treatment.
In Brief
Penn Medicine received a $10 million gift from Cynthia King, the late Jeffery King, and Jason and Julie Borrelli to establish the King Center for Lynch Syndrome, at the Abramson Cancer Center of the University of Pennsylvania.
In Brief
The University of Hawaiʻi Cancer Center’s Epidemiology Division was the victim of a cyberattack that possibly exposed records containing Social Security numbers and driver’s license numbers, mostly from Hawaiʻi DL records collected in 2000 from the State Department of Transportation (when identifiers were usually SSNs) and City and County of Honolulu voter registration records collected in 1998 (also when identifiers were usually SSNs).
Clinical Roundup
Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.
Clinical Roundup
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.
Clinical Roundup
Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data—including laboratory results, genetic sequencing and imaging data—in one setting.
Clinical Roundup
Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence-based liquid biopsy test using genome-wide cell-free DNA fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden.
Clinical Roundup
About 50% of triple-negative breast cancer patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly reducing the chances of survival.
Clinical Roundup
A study led by researchers at St. Jude Children’s Research Hospital shows that microbial cell-free DNA sequencing can predict bloodstream infections in children with leukemia days before the infection is apparent.
Clinical Roundup
A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.
Drugs & Targets
FDA has approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Drugs & Targets
FDA has granted tentative approval for the Abbreviated New Drug Application for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of Lutathera (lutetium Lu 177 dotatate), which is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Drugs & Targets
Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
NCI Trials
The National Cancer Institute approved the following clinical research studies last month.
Podcast
Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claimed that Tempus AI Inc., an AI-driven precision and genomic testing company, had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.
The Directors
“We’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,” said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center.
Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claim that Tempus AI Inc. had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.
Podcast
Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.
The Stephenson Global Pancreatic Cancer Research Institute, established a little over a year ago with a $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, has refined its goals.
Guest Editorial
Radiology departments have tried for years to “own” or “fix” clinical trials imaging assessment workflows by extending clinical tools (PACS, worklists, dictation systems) and habits (speed, seamlessness, few clicks) into the research world.
Cancer Policy
Former members of the U.S. Preventative Services Task Force are sounding alarm about an apparent plan by HHS to eliminate the highly respected and influential 16-member expert panel.
Cancer Policy
HHS leadership has announced they will be pursuing steps to “crack down on fraud in Medicare and Medicaid.”
Cancer Policy
FDA issued draft guidance for sponsors seeking full approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety when randomized controlled trials are not feasible due to small patient populations.
In Brief
After more than 18 years leading Georgetown University’s Lombardi Comprehensive Cancer Center, including four consecutive Cancer Center Support Grant renewals, Louis M. Weiner has announced his decision to step down later this year.
In Brief
Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.
In Brief
David Weinberg was named vice president/physician lead of Fox Chase Cancer Center’s Cancer Screening and Prevention Service Line and associate director of Cancer Screening and Prevention for the Institute for Cancer Research.
In Brief
Bob Purcell was named chief communications officer at The Parker Institute for Cancer Immunotherapy.
In Brief
Frank Smith was named president of XenoSTART’s preclinical business unit at the START Center for Cancer Research.
In Brief
The Advanced Research Projects Agency for Health, an agency within HHS, announced the seven research teams across the United States funded through its PROactive Solutions for Prolonging Resilience program.
Clinical Roundup
High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).
Clinical Roundup
The results from first-in-human portion of the ongoing phase I/II PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation highlighted the antitumor activity of rezatapopt in heavily pretreated patients across multiple solid tumor-types, establishing proof-of-concept for p53 reactivation.
Clinical Roundup
Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.
Clinical Roundup
ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint.
